Research-Based Insights Showcase the Benefits of the OneOncology Platform

Nashville, TN – October 7, 2020 – OneOncology, the partnership of independent community oncology practices, said today that physicians, pharmacists and value-based care experts across the OneOncology network will present five posters at the American Society of Clinical Oncology’s (ASCO) virtual Quality and Care Symposium and seven additional posters focused on insights from partner practice, Tennessee Oncology. The symposium begins October 9.

The posters highlight research-based insights to improve oncology care derived from practices across the OneOncology platform as well as in Tennessee Oncology’s heterogeneous practice setting. Using data gathered at different practices sites gives important insights into the real-world use of therapeutics, technologies and physician engagement initiatives at community oncology practice throughout the U.S.

“These posters showcase the value partner practices gain by leveraging the expertise and economies of scale within the OneOncology network,” said Jeff Patton, MD, CEO, OneOncology. “Whether it’s savings from utilizing biosimilars, initiatives to reduce variation of oral breakthrough antiemetic medications to optimize clinical care or the benefits of conducting virtual tumor boards with colleagues across the network, our team’s presentations give a snap shot into our research-based approach to improve the lives of everyone living with cancer.”

In one poster presentation, OneOncology experts show that use of two biosimilars increased dramatically at all practices resulting in a $4.4 million decrease in cost compared to the originator therapy during just one study period. Another poster reveals that when a comprehensive treatment plan contains a prompt in the Electronic Medical Record, it can markedly increase appropriate utilization. And a third another poster reveals the strong physician engagement on OneCommunity, an internal physician-focused social media network, on which 277 physicians presented 71 individual patient cases across 10 specialty tumor boards since its launch earlier this year.  

The full roster of OneOncology posters:  

• Feasibility of and associated cost savings from transitioning to therapeutic biosimilar use in a large community oncology network.
• Impact of a built-in electronic medical record prompt on guideline-recommended prophylactic antiviral usage in patients with multiple myeloma receiving proteasome inhibitors.
• Use of antiemetic prophylaxis and oral breakthrough medication for highly emetogenic chemotherapy (HEC) in a large community oncology network. 
• Finding value in social media: A collaborative online communication platform linking providers to education and an online tumor board across a large community of oncology practices.
• Real-world patterns of chemotherapy and immunotherapy utilization at end of life in a large community oncology network.

The full roster of Tennessee Oncology posters:

• The effects of COVID-19 on new oral oncolytic treatments
• Maintaining treatment volumes during the COVID-19 pandemic
• Electronic patient-reported outcomes (ePRO) platform engagement in cancer patients during COVID-19
• The effect of COVID-19 on revenue cycle staff
• Using retrospective adverse event data to assess the impact of visitor management during a pandemic emergency plan at a community oncology practice
• Utilization of telemedicine to meet the demand throughout the COVID-19 pandemic at a community oncology practice
• Providing uninterrupted oral oncolytic therapies during the COVID-19 pandemic